Physician profile

Michael D Tran

Dentist · Houston, TX

NPI 1477951382

$2,761.50

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Debt Forgiveness$1,753.65
Entertainment$261.05
Food and Beverage$18.15

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Align Technology, INC. $1,819.65 2019-2024 Itero, Invisalign
A-Dec, INC. $502.50 2021
Keystone Dental INC. $261.05 2023
Kerr Corporation $61.69 2019-2020
Coltene Whaledent INC. $36.91 2021
Nobel Biocare USA $27.55 2022
Pacira Pharmaceuticals Incorporated $22.92 2022
Envista Holdings Corporation $18.15 2024 Maxcem Elite
Dentsply Sirona INC $11.08 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael D Tran

$2,761.50

in general payments reported 2019-2025

Years
2019-2024
Top company
Align Technology, INC.

https://glasscript.com/doctor/1282246/michael-d-tran

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.